For research use only. Not for therapeutic Use.
The metabolism of F series prostaglandins (PGs), including PGF<sub>1α</sub> and PGF<sub>2α</sub>, commonly begins with the reduction of the double bond between C-<wbr></wbr>13 and C-<wbr></wbr>14 and oxidation of the hydroxyl group at C-<wbr></wbr>15, producing 13,14-<wbr></wbr>dihydro-<wbr></wbr>15-<wbr></wbr>keto PGs. The removal of four carbons at the α-<wbr></wbr>terminus and oxidation of the terminal ω carbon produces the abundant urinary metabolites, including tetranor-<wbr></wbr>PGFM. 13,14-<wbr></wbr>dihydro-<wbr></wbr>15-<wbr></wbr>keto tetranor PGF<sub>1α</sub> is a potential metabolite of either PGF<sub>1α</sub> or PGF<sub>2α</sub> and likely precursor to tetranor-<wbr></wbr>PGFM.
| Catalog Number | R064505 |
| CAS Number | 24379-94-0 |
| Synonyms | 9α,11α-dihydroxy-15-oxo-2,3,4,5-tetranor prostanoic acid |
| Molecular Formula | C16H28O5 |
| Purity | ≥95% |
| Storage | -20°C |
| IUPAC Name | 3-[(1R,2R,3R,5S)-3,5-dihydroxy-2-(3-oxooctyl)cyclopentyl]propanoic acid |
| InChI | InChI=1S/C16H28O5/c1-2-3-4-5-11(17)6-7-12-13(8-9-16(20)21)15(19)10-14(12)18/h12-15,18-19H,2-10H2,1H3,(H,20,21)/t12-,13-,14-,15+/m1/s1 |
| InChIKey | UIZLUZTVNFGFMX-TUVASFSCSA-N |
| SMILES | CCCCCC(=O)CCC1C(CC(C1CCC(=O)O)O)O |
| Reference | 1.Granström, E., and Samuelsson, B. The structure of a urinary metabolite of prostaglandin F2α in man. Journal of the American Chemical Society 91, 3398-3400 (1969). |
